Achilles Therapeutics PLC ADR
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $43.80 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Achilles Therapeutics PLC ADR had its IPO on 2021-03-31 under the ticker symbol ACHL.
The company operates in the Healthcare sector and Biotechnology industry. Achilles Therapeutics PLC ADR has a staff strength of 242 employees.
Shares of Achilles Therapeutics PLC ADR opened at $1.03 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $0.97 - $1.04, and closed at $1.02.
This is a -1.22% slip from the previous day's closing price.
A total volume of 35,926 shares were traded at the close of the day’s session.
In the last one week, shares of Achilles Therapeutics PLC ADR have slipped by -3.56%.
Achilles Therapeutics PLC ADR's Key Ratios
Achilles Therapeutics PLC ADR has a market cap of $43.80 million, indicating a price to book ratio of 0.2627 and a price to sales ratio of 0.
In the last 12-months Achilles Therapeutics PLC ADR’s revenue was $0 with a gross profit of $0 and an EBITDA of $-70313000. The EBITDA ratio measures Achilles Therapeutics PLC ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Achilles Therapeutics PLC ADR’s operating margin was 0% while its return on assets stood at -16.6% with a return of equity of -25.74%.
In Q3, Achilles Therapeutics PLC ADR’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Achilles Therapeutics PLC ADR’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.63 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Achilles Therapeutics PLC ADR’s profitability.
Achilles Therapeutics PLC ADR stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 1.5901. Its price to sales ratio in the trailing 12-months stood at 0.
Achilles Therapeutics PLC ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $227.35 million
- Total Liabilities
- $19.06 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Achilles Therapeutics PLC ADR ended 2023 with $227.35 million in total assets and $0 in total liabilities. Its intangible assets were valued at $227.35 million while shareholder equity stood at $202.62 million.
Achilles Therapeutics PLC ADR ended 2023 with $0 in deferred long-term liabilities, $19.06 million in other current liabilities, 54000.00 in common stock, $-166231000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $179.89 million and cash and short-term investments were $179.89 million. The company’s total short-term debt was $4,036,000 while long-term debt stood at $0.
Achilles Therapeutics PLC ADR’s total current assets stands at $198.69 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $10.71 million compared to accounts payable of $7.52 million and inventory worth $0.
In 2023, Achilles Therapeutics PLC ADR's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Achilles Therapeutics PLC ADR paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Achilles Therapeutics PLC ADR stock is currently trading at $1.02 per share. It touched a 52-week high of $3.45 and a 52-week low of $3.45. Analysts tracking the stock have a 12-month average target price of $10.75.
Its 50-day moving average was $0.93 and 200-day moving average was $1.54 The short ratio stood at 0.19 indicating a short percent outstanding of 0%.
Around 490.2% of the company’s stock are held by insiders while 5968.2% are held by institutions.
Frequently Asked Questions About Achilles Therapeutics PLC ADR
Similar Industry Stocks (Biotechnology)
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company’s lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.